Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasodine for common cold
ACTRN12621000604808Phase 3Completed
- Sponsor
- Firebrick Pharma
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in nasopharyngitis comparing Nasodine nasal spray with Matching placebo nasal spray (2 arms). Primary endpoint: WURSS-21 Global Severity Score in virus-confirmed participants excluding SARS-CoV-2. Started May 2022; status: completed.
02
Drugs
Nasodine
03
Conditions
nasopharyngitis
Beyond the preview
Go deeper on ACTRN12621000604808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000604808.